DURECT Corporation (DRRX): Price and Financial Metrics

DURECT Corporation (DRRX): $1.41

-0.10 (-6.62%)

POWR Rating

Component Grades














  • Value is the dimension where DRRX ranks best; there it ranks ahead of 65% of US stocks.
  • The strongest trend for DRRX is in Momentum, which has been heading down over the past 31 weeks.
  • DRRX's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).

DRRX Stock Summary

  • With a one year PEG ratio of 407.95, Durect Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 91.32% of US stocks.
  • With a price/sales ratio of 11.31, Durect Corp has a higher such ratio than 83.49% of stocks in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for DRRX comes in at -19.73% -- higher than that of just 13.48% of stocks in our set.
  • Stocks that are quantitatively similar to DRRX, based on their financial statements, market capitalization, and price volatility, are ELSE, INGN, ESP, WHLM, and EEFT.
  • DRRX's SEC filings can be seen here. And to visit Durect Corp's official web site, go to www.durect.com.

DRRX Valuation Summary

  • DRRX's price/sales ratio is 11.4; this is 216.67% higher than that of the median Healthcare stock.
  • DRRX's price/sales ratio has moved down 131.6 over the prior 243 months.
  • DRRX's price/sales ratio has moved down 131.6 over the prior 243 months.

Below are key valuation metrics over time for DRRX.

Stock Date P/S P/B P/E EV/EBIT
DRRX 2018-05-09 6.5 10.3 -80.5 -207.1
DRRX 2016-05-16 9.1 16.0 -6.4 -7.7
DRRX 2015-09-02 14.1 10.9 -10.7 -12.5
DRRX 2015-02-20 5.8 4.8 -5.3 -6.1
DRRX 2006-07-11 7.5 5.5 -11.3 -15.6
DRRX 2002-06-27 54.9 4.2 -7.4 -7.2

DRRX Growth Metrics

  • Its 3 year price growth rate is now at -31.28%.
  • Its year over year net cashflow from operations growth rate is now at -1037.98%.
  • Its 3 year revenue growth rate is now at 6.95%.
DRRX's revenue has moved up $15,523,000 over the prior 52 months.

The table below shows DRRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 29.548 -36.553 -0.768
2020-12-31 30.111 -38.704 -0.582
2020-09-30 41.987 -26.347 -9.173
2020-06-30 50.067 1.126 -1.831
2020-03-31 28.208 3.897 -23.396
2019-12-31 29.564 11.101 -20.578

DRRX Price Target

For more insight on analysts targets of DRRX, see our DRRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $7.00 Average Broker Recommendation 1.4 (Strong Buy)

DRRX Stock Price Chart Interactive Chart >

Price chart for DRRX

DRRX Price/Volume Stats

Current price $1.41 52-week high $2.95
Prev. close $1.51 52-week low $1.28
Day low $1.35 Volume 955,005
Day high $1.47 Avg. volume 1,353,826
50-day MA $1.59 Dividend yield N/A
200-day MA $1.91 Market Cap 320.64M

DURECT Corporation (DRRX) Company Bio

DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. The company was founded in 1998 and is based in Cupertino, California.

DRRX Latest News Stream

Event/Time News Detail
Loading, please wait...

DRRX Latest Social Stream

Loading social stream, please wait...

View Full DRRX Social Stream

Latest DRRX News From Around the Web

Below are the latest news stories about Durect Corp that investors may wish to consider to help them evaluate DRRX as an investment opportunity.

DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29

DURECT Corporation (Nasdaq: DRRX) today announced that it will report its second quarter 2021 financial results and host a conference call after the market close on Thursday, July 29, 2021.

Yahoo | July 22, 2021

DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit

DURECT Corporation (Nasdaq: DRRX) today announced it will present at the Epigenetic Therapeutic Targets Summit, being held virtually July 13-15, 2021.

Yahoo | July 14, 2021

Here's What DURECT Corporation's (NASDAQ:DRRX) Shareholder Ownership Structure Looks Like

The big shareholder groups in DURECT Corporation ( NASDAQ:DRRX ) have power over the company. Generally speaking, as a...

Yahoo | June 25, 2021

DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL)

DURECT Corporation (Nasdaq: DRRX) today announced the presentation of additional clinical data from a DUR-928 Phase 1b trial in non-alcoholic steatohepatitis (NASH) and a Phase 1 trial in subjects with hepatic impairment (HI) as part of two posters at the 2021 International Liver Conference (EASL) being held virtually June 23-26, 2021.

Yahoo | June 23, 2021

DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)

DURECT Corporation (Nasdaq: DRRX) today announced it will present two posters at the 2021 International Liver Conference (EASL) to be held virtually June 23-26 , 2021.

BioSpace | June 8, 2021

Read More 'DRRX' Stories Here

DRRX Price Returns

1-mo -13.50%
3-mo -25.79%
6-mo -31.55%
1-year -27.32%
3-year -4.08%
5-year -27.32%
YTD -31.88%
2020 -45.53%
2019 691.67%
2018 -47.83%
2017 -31.34%
2016 -39.37%

Continue Researching DRRX

Here are a few links from around the web to help you further your research on Durect Corp's stock as an investment opportunity:

Durect Corp (DRRX) Stock Price | Nasdaq
Durect Corp (DRRX) Stock Quote, History and News - Yahoo Finance
Durect Corp (DRRX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7979 seconds.